vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2015-3-83-88vtio-570Research ArticleОбзор литературыLiterature ReviewsЛЕЧЕНИЕ ГЕПАТИТА C БЕЗ ИСПОЛЬЗОВАНИЯ ПРЕПАРАТОВ ИНТЕРФЕРОНА У БОЛЬНЫХ, ПЕРЕНЕСШИХ ТРАНСПЛАНТАЦИЮ ПЕЧЕНИTREATMENT OF HEPATITIS C WITHOUT INTERFERON IN PATIENTS UNDERGOING LIVER TRANSPLANTATIONХубутияМ. Ш.KhubutiaM. Sh.СюткинВ. Е.SyutkinV. E.

129010, г. Москва, Б. Сухаревская пл., д. 3, корп. 9. Тел. (903) 127-94-78.

3/9, B. Sukharevskaya sg., Moscow, 129010, Russian Federation. Tel. (903) 127-94-78

vladsyutkin@gmail.comГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского», Москва, Российская ФедерацияРоссияN.V. Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russian FederationRussian Federation2015091020151738388Copyright © Хубутия М.Ш., Сюткин В.Е., 20152015Хубутия М.Ш., Сюткин В.Е.Khubutia M.S., Syutkin V.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/570

В обзоре представлен анализ текущего состояния проблемы противовирусной терапии хронического гепатита С у пациентов, перенесших трансплантацию печени. В работе рассматриваются основные ограничения, связанные с применением существующих на рынке препаратов, и предпосылки к внедрению новых схем, не содержащих интерферона. Представлен обзор опубликованных к настоящему времени исследований, посвященных применению препаратов прямого противовирусного действия с основными результатами и выводами

This review contains analysis of current approaches to HCV treatment in liver transplant recipients. The authors explore key limitations associated with the usage of available treatment options and benefi ts related to the implementation of IFN-free regimens. The review summarizes results of published up-to-date studies on the usage of direct antiviral agents after liver transplantation.

трансплантация печенихронический гепатит Спротивовирусные препаратыliver transplantationchronic hepatitis Cantiviral drugsReferencesScientifi c Registry of Transplant Recipients 2012 annual data report. Rockville, MD: Health Resources and Services Administration. 2012; Available from: http:// srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf.Scientifi c Registry of Transplant Recipients 2012 annual data report. Rockville, MD: Health Resources and Services Administration. 2012; Available from: http:// srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf.World Health Organ ization, Spanish National Transplant Organization. Global observatory on donation and transplantation.2012; Available from: http://issuu.com/o-n-t/docs/2012ad.World Health Organ ization, Spanish National Transplant Organization. Global observatory on donation and transplantation.2012; Available from: http://issuu.com/o-n-t/docs/2012ad.Berenguer M, Ferre ll L, Watson J et al. HCV-related fi brosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32 (4): 673–684.Berenguer M, Ferre ll L, Watson J et al. HCV-related fi brosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32 (4): 673–684.Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999; 29 (1): 250–256.Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999; 29 (1): 250–256.Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological fi ndings and application of consensus criteria. Liver Transpl. 2010; 16 (11): 1228–1235.Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological fi ndings and application of consensus criteria. Liver Transpl. 2010; 16 (11): 1228–1235.Crespo G, Marino Z, N avasa M et al. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142 (6):1373–1383 e1371.Crespo G, Marino Z, N avasa M et al. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142 (6):1373–1383 e1371.Terrault NA and Bereng uer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl.2006; 12 (8): 1192–1204.Terrault NA and Bereng uer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl.2006; 12 (8): 1192–1204.Levitsky J, Fiel MI, No rvell JP et al. Risk for immunemediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012; 142 (5): 1132–1139 e1131.Levitsky J, Fiel MI, No rvell JP et al. Risk for immunemediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012; 142 (5): 1132–1139 e1131.Berenguer M, Palau A, Ag uilera V et al. Clinical benefi ts of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8 (3): 679–687.Berenguer M, Palau A, Ag uilera V et al. Clinical benefi ts of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8 (3): 679–687.Gurusamy Ks TE, Xiroucha kis E, Burroughs Ak, Davidson Br. Antiviral therapy for recurrent liver graft infection with hepatitis C virus (Review). 2010.Gurusamy Ks TE, Xiroucha kis E, Burroughs Ak, Davidson Br. Antiviral therapy for recurrent liver graft infection with hepatitis C virus (Review). 2010.Selzner N, Guindi M, Ren ner EL et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol. 2011; 55 (1): 207–217.Selzner N, Guindi M, Ren ner EL et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol. 2011; 55 (1): 207–217.Coilly A, Roche B, Dumort ier J et al. Safety and effi cacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60 (1): 78–86.Coilly A, Roche B, Dumort ier J et al. Safety and effi cacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60 (1): 78–86.Pungpapong S, Aqel BA, Kon ing L et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19 (7): 690–700.Pungpapong S, Aqel BA, Kon ing L et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19 (7): 690–700.Burton JRJr, O'leary JG, Ve rna EC et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014; 61 (3): 508–514.Burton JRJr, O'leary JG, Ve rna EC et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014; 61 (3): 508–514.Saab S, Manne V, Bau S et al . Boceprevir in liver transplant recipients. Liver Int. 2014.Saab S, Manne V, Bau S et al . Boceprevir in liver transplant recipients. Liver Int. 2014.Gentile I, Borgia F, Buonomo AR et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Current medicinal chemistry. 2014; 21 (28): 3261–3270.Gentile I, Borgia F, Buonomo AR et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Current medicinal chemistry. 2014; 21 (28): 3261–3270.Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370 (17): 1594–1603.Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370 (17): 1594–1603.Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370 (17): 1604–1614.Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370 (17): 1604–1614.Ferenci P, Bernstein D, Lalezar i J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370 (21): 1983–1992.Ferenci P, Bernstein D, Lalezar i J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370 (21): 1983–1992.Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147 (2):359–365 e351.Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147 (2):359–365 e351.Poordad F, Hezode C, Trinh R et a l. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370 (21): 1973–1982.Poordad F, Hezode C, Trinh R et a l. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370 (21): 1973–1982.Samuel D, Charlton M, Gane E et al . Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter Study. J Hepatol. 2014; 60 (Suppl.): S26.Samuel D, Charlton M, Gane E et al . Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter Study. J Hepatol. 2014; 60 (Suppl.): S26.Reddy K, Everson GT, Flamm SL et a l. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, 2014; 8.Reddy K, Everson GT, Flamm SL et a l. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, 2014; 8.Brown RS, Reddy K, O'leary JG et a l. Safety and Effi cacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, 2014; LB-4.Brown RS, Reddy K, O'leary JG et a l. Safety and Effi cacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, 2014; LB-4.Levin RBJ. Safety and Effi cacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts,2014; Available from: http://www.natap.org/2014/ AASLD/AASLD_19.htm.Levin RBJ. Safety and Effi cacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts,2014; Available from: http://www.natap.org/2014/ AASLD/AASLD_19.htm.Kwo PY, Mantry PS, Coakley E et al . An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. N Engl J Med. 2014; 371 (25): 2375–2382.Kwo PY, Mantry PS, Coakley E et al . An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. N Engl J Med. 2014; 371 (25): 2375–2382.

The authors declare that there are no conflicts of interest present.